Table_2_Landscape and predictions of inflammatory bowel disease in China: China will enter the Compounding Prevalence stage around 2030.pdf

BackgroundThis study aims to explore the epidemiological trends of inflammatory bowel disease (IBD) over the past three decades in China and further predict the trends of IBD in the next 25 years.MethodsThe prevalence, incidence, mortality, years of life lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and annual percentage changes of the above metrics of IBD in China from 1990 to 2019 were extracted from the Global Burden of Disease Study 2019. The corresponding trends in the next 25 years were predicted.ResultsFrom 1990 to 2019, the cases of IBD in China raised to 484 thousand [95% uncertainty interval (UI) 411–571] and 427 thousand (366–498) among males and females, respectively. The age-standardized incidence rate of IBD increased from 1.72 per 100,000 population (1.44–2.05) to 3.35 per 100,000 population (2.88–3.88) among males and from 1.20 per 100,000 population (1.02–1.42) to 2.65 per 100,000 population (2.29–3.08) among females. The highest incidence rate occurred in people aged 35–39 years. The total YLDs attributed to IBD significantly increased, but the YLLs showed a decreasing trend, resulting in minor alterations of the DALYs. In the next 25 years, the incidence of IBD would continue to increase until a plateau by 2030, and IBD-related deaths would also increase to about 7.57 thousand by 2044 despite the decreasing age-standardized mortality rate. Similar trends were observed for both sexes, with a slight male predominance.ConclusionsAlthough China is still a low-endemic area of IBD, the prevalence and incidence of IBD dramatically increased in the past three decades. The burden of IBD in China is expected to grow continuously in the next 25 years due to the large population base and severe aging problem. China is estimated to enter the Compounding Prevalence stage around 2030.</p

Table_1_Landscape and predictions of inflammatory bowel disease in China: China will enter the Compounding Prevalence stage around 2030.pdf

BackgroundThis study aims to explore the epidemiological trends of inflammatory bowel disease (IBD) over the past three decades in China and further predict the trends of IBD in the next 25 years.MethodsThe prevalence, incidence, mortality, years of life lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and annual percentage changes of the above metrics of IBD in China from 1990 to 2019 were extracted from the Global Burden of Disease Study 2019. The corresponding trends in the next 25 years were predicted.ResultsFrom 1990 to 2019, the cases of IBD in China raised to 484 thousand [95% uncertainty interval (UI) 411–571] and 427 thousand (366–498) among males and females, respectively. The age-standardized incidence rate of IBD increased from 1.72 per 100,000 population (1.44–2.05) to 3.35 per 100,000 population (2.88–3.88) among males and from 1.20 per 100,000 population (1.02–1.42) to 2.65 per 100,000 population (2.29–3.08) among females. The highest incidence rate occurred in people aged 35–39 years. The total YLDs attributed to IBD significantly increased, but the YLLs showed a decreasing trend, resulting in minor alterations of the DALYs. In the next 25 years, the incidence of IBD would continue to increase until a plateau by 2030, and IBD-related deaths would also increase to about 7.57 thousand by 2044 despite the decreasing age-standardized mortality rate. Similar trends were observed for both sexes, with a slight male predominance.ConclusionsAlthough China is still a low-endemic area of IBD, the prevalence and incidence of IBD dramatically increased in the past three decades. The burden of IBD in China is expected to grow continuously in the next 25 years due to the large population base and severe aging problem. China is estimated to enter the Compounding Prevalence stage around 2030.</p

Image_1_Landscape and predictions of inflammatory bowel disease in China: China will enter the Compounding Prevalence stage around 2030.pdf

BackgroundThis study aims to explore the epidemiological trends of inflammatory bowel disease (IBD) over the past three decades in China and further predict the trends of IBD in the next 25 years.MethodsThe prevalence, incidence, mortality, years of life lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and annual percentage changes of the above metrics of IBD in China from 1990 to 2019 were extracted from the Global Burden of Disease Study 2019. The corresponding trends in the next 25 years were predicted.ResultsFrom 1990 to 2019, the cases of IBD in China raised to 484 thousand [95% uncertainty interval (UI) 411–571] and 427 thousand (366–498) among males and females, respectively. The age-standardized incidence rate of IBD increased from 1.72 per 100,000 population (1.44–2.05) to 3.35 per 100,000 population (2.88–3.88) among males and from 1.20 per 100,000 population (1.02–1.42) to 2.65 per 100,000 population (2.29–3.08) among females. The highest incidence rate occurred in people aged 35–39 years. The total YLDs attributed to IBD significantly increased, but the YLLs showed a decreasing trend, resulting in minor alterations of the DALYs. In the next 25 years, the incidence of IBD would continue to increase until a plateau by 2030, and IBD-related deaths would also increase to about 7.57 thousand by 2044 despite the decreasing age-standardized mortality rate. Similar trends were observed for both sexes, with a slight male predominance.ConclusionsAlthough China is still a low-endemic area of IBD, the prevalence and incidence of IBD dramatically increased in the past three decades. The burden of IBD in China is expected to grow continuously in the next 25 years due to the large population base and severe aging problem. China is estimated to enter the Compounding Prevalence stage around 2030.</p

Image_2_Landscape and predictions of inflammatory bowel disease in China: China will enter the Compounding Prevalence stage around 2030.pdf

BackgroundThis study aims to explore the epidemiological trends of inflammatory bowel disease (IBD) over the past three decades in China and further predict the trends of IBD in the next 25 years.MethodsThe prevalence, incidence, mortality, years of life lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and annual percentage changes of the above metrics of IBD in China from 1990 to 2019 were extracted from the Global Burden of Disease Study 2019. The corresponding trends in the next 25 years were predicted.ResultsFrom 1990 to 2019, the cases of IBD in China raised to 484 thousand [95% uncertainty interval (UI) 411–571] and 427 thousand (366–498) among males and females, respectively. The age-standardized incidence rate of IBD increased from 1.72 per 100,000 population (1.44–2.05) to 3.35 per 100,000 population (2.88–3.88) among males and from 1.20 per 100,000 population (1.02–1.42) to 2.65 per 100,000 population (2.29–3.08) among females. The highest incidence rate occurred in people aged 35–39 years. The total YLDs attributed to IBD significantly increased, but the YLLs showed a decreasing trend, resulting in minor alterations of the DALYs. In the next 25 years, the incidence of IBD would continue to increase until a plateau by 2030, and IBD-related deaths would also increase to about 7.57 thousand by 2044 despite the decreasing age-standardized mortality rate. Similar trends were observed for both sexes, with a slight male predominance.ConclusionsAlthough China is still a low-endemic area of IBD, the prevalence and incidence of IBD dramatically increased in the past three decades. The burden of IBD in China is expected to grow continuously in the next 25 years due to the large population base and severe aging problem. China is estimated to enter the Compounding Prevalence stage around 2030.</p

Nonadiabatic Curve-Crossing Model for the Visible-Light Photoredox Catalytic Generation of Radical Intermediate via a Concerted Mechanism

Photoredox catalysis relies on the excited-state single-electron transfer (SET) processes to drive a series of unique bond-forming reactions. In this work accurate electronic structure calculations at the CASPT2//CASSCF/PCM level of theory together with the kinetic assessment of SETs and intersystem crossing are employed to provide new insights into the SET initiation, activation, and deactivation by calculating the SET paths for a paradigm example of photoredox α-vinylation reaction mediated by iridium­(III) catalysts. The concerted photocatalysis mechanism described by the nonadiabatic curve-crossing model, in essence of Marcus electron transfer theory, is first applied for the mechanistic description of the SET events in visible-light photoredox catalysis. The C–C bond functionalization has been revealed to take place in a concerted manner along an energy-saving pathway, in which the generated α-amino radical is unlikely independent existence but strongly depends on the mutual interaction with different substrates. These mechanistic insights offer a plausible picture for the excited-state SET-mediated chemical transformations that should be applicable to further studies of photoredox catalysis in organic chemistry

Table_3_Landscape and predictions of inflammatory bowel disease in China: China will enter the Compounding Prevalence stage around 2030.pdf

BackgroundThis study aims to explore the epidemiological trends of inflammatory bowel disease (IBD) over the past three decades in China and further predict the trends of IBD in the next 25 years.MethodsThe prevalence, incidence, mortality, years of life lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life years (DALYs), and annual percentage changes of the above metrics of IBD in China from 1990 to 2019 were extracted from the Global Burden of Disease Study 2019. The corresponding trends in the next 25 years were predicted.ResultsFrom 1990 to 2019, the cases of IBD in China raised to 484 thousand [95% uncertainty interval (UI) 411–571] and 427 thousand (366–498) among males and females, respectively. The age-standardized incidence rate of IBD increased from 1.72 per 100,000 population (1.44–2.05) to 3.35 per 100,000 population (2.88–3.88) among males and from 1.20 per 100,000 population (1.02–1.42) to 2.65 per 100,000 population (2.29–3.08) among females. The highest incidence rate occurred in people aged 35–39 years. The total YLDs attributed to IBD significantly increased, but the YLLs showed a decreasing trend, resulting in minor alterations of the DALYs. In the next 25 years, the incidence of IBD would continue to increase until a plateau by 2030, and IBD-related deaths would also increase to about 7.57 thousand by 2044 despite the decreasing age-standardized mortality rate. Similar trends were observed for both sexes, with a slight male predominance.ConclusionsAlthough China is still a low-endemic area of IBD, the prevalence and incidence of IBD dramatically increased in the past three decades. The burden of IBD in China is expected to grow continuously in the next 25 years due to the large population base and severe aging problem. China is estimated to enter the Compounding Prevalence stage around 2030.</p

Independent-samples t-test based on alerting level groups.

<p>NB. EC  =  executive control; CAE  =  conflict adaptation effect on change trials; RPE  =  repetition priming effect on the response or S-R repetition trials; conflict  =  congruency effects in the flanker task; RTs  =  reactive times in the task; and error  =  error rate in the task, respectively.</p

Correlations between the related factors in Experiment 1.

**<p>. Correlation is significant at the .01 level (2-tailed).</p>*<p>. Correlation is significant at the .05 level (2-tailed).</p><p>c. Unless otherwise noted, bootstrap results are based on 5000 bootstrap samples</p><p>NB. EC  =  executive control; CAE  =  conflict adaptation effect on change trials; RPE  =  repetition priming effect on the response or S-R repetition trials; and conflict  =  congruency effects in the flanker task; CI  =  Confidence Interval, respectively.</p

Scatter distribution in experiment 1.

<p>Curve fit between the efficiency of alertness and the CAE, alertness and the RPE, alertness and the congruency effect, respectively. NB. CAE  =  conflict adaptation effect on change trials; RPE  =  repetition priming effect on response or stimulus-response (S-R) repetition trials.</p

Mean RTs for each combination of current type and previous type in the two groups.

<p>Panel A shows the results on change trials of the high alerting level group and the low alerting level group. Panel B shows the results in the response or S-R repetition trials of the high alerting level group and the low alerting level group.</p